Drugs / Ad26.COV2.S
Ad26.COV2.S
also known as
Ad26COVS1 · JNJ-78436735 · Johnson & Johnson · COVID-19 Vaccine Janssen · Janssen · Janssen COVID19 vaccine · Johnson \& Johnson Vaccine · VAC31518
Trials 26 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04894305 | May → Dec 2021 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 1 | NCT04509947 | Aug 2020 → Feb 2021 | — | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05109559 | Dec 2021 → Dec 2023 | COVID-19 | Mahidol University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04889209 | May 2021 → Jun 2023 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/2 | NCT04436276 | Jul 2020 → Feb 2023 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT05409261 | Jun → Sep 2022 | COVID-19 | ANRS, Emerging Infectious Diseases | Unknown | No outcome recorded |
| Phase 2 | NCT07408297 | May 2022 → Jun 2024 | COVID-19 | Victoria Biomedical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT04998240 | Dec 2021 → Sep 2022 | COVID-19 | International Vaccine Institute | Unknown | No outcome recorded |
| Phase 2 | NCT05007080 | Sep 2021 → Aug 2023 | COVID-19 | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 2 | NCT04765384 | Aug 2021 → Nov 2023 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 2 | NCT05000216 | Aug 2021 → Jun 2023 | juvenile dermatomyositis, juvenile idiopathic arthritis, pediatric multiple sclerosis, pediatric systemic lupus erythematosus +3 | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 2 | NCT04999111 | Aug → Oct 2021 | COVID-19 | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 2 | NCT05324319 | Jun 2021 → Jul 2022 | COVID-19 | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 2 | NCT04535453 | Aug 2020 → Mar 2022 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 38 trials | ||||||
| Phase 3 | NCT05148845 | Nov 2021 → Jan 2022 | COVID-19 | Wits Health Consortium (Pty) Ltd | Unknown | No outcome recorded |
| Phase 3 | NCT05091307 | Nov 2021 → Jun 2022 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 3 | NCT05028257 | Sep 2021 → May 2023 | anaphylaxis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT05047640 | Sep 2021 → Oct 2022 | COVID-19 | Giselle Guerra | Terminated | No outcome recorded |
| Phase 3 | NCT04908722 | Jun 2021 → Jul 2023 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 3 | NCT04838795 | Feb 2021 → Mar 2022 | severe acute respiratory syndrome | Wits Health Consortium (Pty) Ltd | Completed | No outcome recorded |
| Phase 3 | NCT04614948 | Nov 2020 → Jun 2023 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 3 | NCT04505722 | Sep 2020 → Mar 2023 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05037266 | Sep 2021 → Feb 2022 | — | University Hospital of Saint-Etienne | Terminated | No outcome recorded |
| Phase 4 | NCT06360744 | Jul 2021 → Dec 2023 | COVID-19 | Jens D Lundgren, MD | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05019456 | Mar 2021 → Dec 2025 overdue | COVID-19, influenza | University of Arizona | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04817657 | — | — | Janssen Research & Development, LLC | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05081271 Comparator | Oct 2021 → May 2022 | multiple sclerosis | Griffin Hospital | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05515042 Comparator | Jul 2022 → Jun 2024 overdue | COVID-19 | The Aurum Institute NPC | Active not recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05030974 Comparator | Oct 2021 → Mar 2022 | COVID-19, kidney disorder | University Medical Center Groningen | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04927936 Comparator | Jun 2021 → Sep 2022 | COVID-19 | Erasmus Medical Center | Unknown | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 31 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad26.COV2.S | “The participants were assigned to receive no booster, an Ad26.COV2.S booster, an mRNA-1273 booster, or a BNT162b2 booster.” PMID 35045226 ↗ Jan 202223“Study products Ad26.COV2.S by Janssen administered as a single dose followed by a single booster injection.” NCT05148845 ↗ “A booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.” NCT05109559 ↗ “This means Ad26.COV2.S if they originally received BNT162b2 or mRNA-1273 or vice versa” NCT05081271 ↗ |
| Known as | Ad26COVS1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05324319 ↗ |
| Known as | COVID-19 Vaccine Janssen | “COVID-19 Vaccine Janssen (Ad26.COV2-S)” NCT05037266 ↗ |
| Known as | Janssen | “SARS-CoV-2 vaccine from Johnson \& Johnson/Janssen” NCT06360744 ↗ |
| Known as | Janssen COVID19 vaccine | “Janssen COVID19 vaccine” NCT05028257 ↗ |
| Known as | JNJ-78436735 | “Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)” NCT05515042 ↗ |
| Known as | Johnson & Johnson | “Healthy physically active participants completed a 20-min bout of graded cycling exercise at intensities corresponding to 50%, 60%, 70%, and 80% of the predetermined V̇O2max...” PMID 34882029 ↗ Dec 2021 |
| Known as | Johnson \& Johnson Vaccine | “using two approved vaccines (Sinopharm / CNBG Vaccine (BBIBP-CorV) and Johnson \& Johnson Vaccine (Ad26.COV2.S)).” NCT04998240 ↗ |
| Known as | VAC31518 | “Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)” NCT05515042 ↗ |
| Modality | Vaccine | “A candidate vaccine, Ad26.COV2.S, is a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein.” PMID 33440088 ↗ Jan 2021 |
| Route | Intramuscular | “Participants will receive intramuscular (IM) injection” NCT04436276 ↗ |